Abstract
The emergence of immune checkpoint inhibitors as effective cancer immunotherapy has effectively built a new “highway” connecting the promise of oncologic translational research to progress in treating advanced malignancies.
| Original language | English |
|---|---|
| Pages (from-to) | 160-2, 176 |
| Number of pages | 4 |
| Journal | Oncology (United States) |
| Volume | 30 |
| Issue number | 2 |
| State | Published - Feb 1 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Animals
- Antineoplastic Agents/therapeutic use
- Carcinoma/drug therapy
- Cell Cycle Checkpoints/drug effects
- Cell Cycle Proteins/antagonists & inhibitors
- Cell Proliferation/drug effects
- Diffusion of Innovation
- Humans
- Immunotherapy
- Molecular Targeted Therapy
- Signal Transduction/drug effects
- Translational Research, Biomedical/trends
- Treatment Outcome
- Urologic Neoplasms/drug therapy
- Urothelium/drug effects
Fingerprint
Dive into the research topics of 'Checkpoint Inhibitors and Urothelial Carcinoma: The Translational Paradigm'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver